Clinical trial NCT04516278: A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
Official title: A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders, NORSE THREE
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Age-related Macular Degeneration
Neovascular Age-related Macular Degeneration
Wet Macular Degeneration
BRVO - Branch Retinal Vein Occlusion
Diabetic Macular Edema
Lead sponsor: Outlook Therapeutics, Inc.
Sponsor class: INDUSTRY
First posted: 2020-08-18
Enrollment: 195
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study will evaluate the safety of ophthalmic bevacizumab in subjects diagnosed with a retinal condition that would benefit from treatment with intravitreal injection of bevacizumab, including: exudative age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion.


Eligibility criteria: Inclusion Criteria:

* Active clinical diagnosis and OCT confirmation of one of the following retinal disorders: exudative age-related macular degeneration (AMD), diabetic macular edema (DME), or branch retinal vein occlusion (BRVO) and, in the opinion of the Investigator, requires treatment with an anti-VEGF therapy

Exclusion Criteria:

* Previous use of approved anti-VEGF or Avastin® within 4 weeks preceding randomization
* Macular edema due to something other than exudative AMD, DME or BRVO, in the study eye
* History of inadequate response to previous intravitreal anti-VEGF therapy
* History of any intraocular or periocular corticosteroid injection or implant, in the study eye
* Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1-month preceding randomization
* Any concurrent intraocular condition in the study eye that may require medical or surgical intervention or contribute to vision loss during the study period
* Active intraocular inflammation in the study eye
* Current vitreous hemorrhage in the study eye
* Polypoidal choroidal vasculopathy (PCV) in the study eye
* History of idiopathic, infectious or autoimmune-associated uveitis in either eye
* Current ocular or periocular infection, such as conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
* Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥30 mmHg despite treatment with anti-glaucoma medication)
* Premenopausal women not using adequate contraception
* Current treatment for active systemic infection
* Known allergy to any component of the study drug , not amenable to treatment

Primary outcomes:
measure: Frequency and incidence of treatment-emergent adverse events
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Tucson
country: United States
facility: Clinical Site
state: Arizona
city: Beverly Hills
country: United States
facility: Clinical Site
state: California
city: Glendale
country: United States
facility: Clinical Site
state: California
city: Long Beach
country: United States
facility: Clinical Site
state: California
city: Palm Desert
country: United States
facility: Clinical Site
state: California
city: Poway
country: United States
facility: Clinical Site
state: California
city: Clearwater
country: United States
facility: Clinical Site
state: Florida
city: Winter Haven
country: United States
facility: Clinical Site
state: Florida
city: Oak Forest
country: United States
facility: Clinical Site
state: Illinois
city: Springfield
country: United States
facility: Clinical Site
state: Illinois
city: Hagerstown
country: United States
facility: Clinical Site
state: Maryland
city: Albuquerque
country: United States
facility: Clinical Site
state: New Mexico
city: Chambersburg
country: United States
facility: Clinical Site
state: Pennsylvania
city: Rapid City
country: United States
facility: Clinical Site
state: South Dakota
city: Germantown
country: United States
facility: Clinical Site
state: Tennessee
city: Abilene
country: United States
facility: Clinical Site
state: Texas
city: Arlington
country: United States
facility: Clinical Site
state: Texas
city: McAllen
country: United States
facility: Clinical Site
state: Texas
city: San Antonio
country: United States
facility: Clinical Site
state: Texas
city: Willow Park
country: United States
facility: Clinical Site
state: Texas
Study officials:
References: